Nuestro equipo

Dra. David Lamas

Dr. David Lamas Francis
Especialista en córnea y superficie ocular

Facultativo especialista en Oftalmología en la Unidad de Córnea y Superficie Ocular del Complejo Hospitalario Universitario de Santiago de Compostela.
Residente de Oftalmología en el Complejo Hospitalario Universitario de Santiago de Compostela.
Curso de especialización en Cirugía Refractiva, Corneal y de Cristalino, Universidad Miguel Hernández, Elche.
Doctorado en Ciencias de la Visión, Universidad de Santiago de Compostela. Tesis doctoral: «Factores de riesgo, perfil microbiológico y tratamiento de las queratitis infecciosas en Galicia».
Fellow of the European Board of Ophthalmology, European Board of Ophthalmology.
Máster en Investigación en Ciencias de la Visión, Universidad de Santiago de Compostela.
Grado en Medicina, Universidad de Santiago de Compostela.

A prospective, randomized, controlled, observer-masked, multicenter clinical trial to demonstrate the safety and effectiveness of the extended depth of focus AT LARA 829MP posterior chamber intraocular lens for correction of aphakia (2026 - presente)
A Phase 3 randomized, masked, controlled trial to evaluate efficacy and safety of belzupacap sarotalocan (AU-011) treatment compared to sham control in subjects with primary indeterminate lesions or small choroidal melanoma (2025 - presente)
REVEAL-2 - a Phase 3, Randomized, Double-masked, Placebo-controlled, ffifficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED) (2025- presente)
REVEAL-1 - a Phase 3, Randomized, Double-masked, Placebo-controlled, ffifficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) (2025 - presente)
A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (HV(s) and Participants With Thyroid Eye Disease (TED). (2024-2025)
Co-THEIA (Combination THerapy with mEthotrexate and adalImumAb for uveitis): Efficacy, safety and cost-effectiveness of methotrexate, adalimumab, or their combination in non infectious non anterior uveitis: a multicenter, randomized, parallel 3 arms, active-controlled, phase 3 open label with blinded outcome assessment study (2024-2025)
Prospective, randomized, double-masked, multicenter post market clinical investigation comparing two dispersive viscosurgical devices: Z-HYALCOAT vs. Healon EndoCoat. Carl Zeiss Meditec AG. (2022-2024)
Multicentric, randomized, comparative clinical study on the evaluation of the efficacy and safety of Neovis® Total Multi vs. Systane® Balance on the treatment of ocular dryness associated with meibomian gland dysfunction. Horus Pharma. (2022-2023)
Prospective, Randomized, Multi-centre, Observer-masked, Non-inferiority Comparison of Two Cohesive Viscoelastic Solutions: VISTHESIA v Provisc. Carl Zeiss Meditec AG. (2020 - 2022)

Lamas-Francis D, Navarro D, Mansilla R, et al. Evaluating medical therapy failure in microbial keratitis: risk factors and management alternatives. Ocul Immunol Inflamm. 2025;33(4):641-648.
Touriño-Peralba R, Rodríguez-Lago J, Lamas-Francis D, et al. Demographic and topographic findings suggesting poor response to crosslinking-iontophoresis in progressive keratoconus. Int Ophthalmol. 2025;45(1):69.
Lamas-Francis D, Navarro D, Mansilla R, et al. Microbial keratitis in north-western Spain: risk factors, microbiological profile and resistance patterns. Eur J Clin Microbiol Infect Dis. 2025;44(1):53-61.
Lamas-Francis D, Navarro D, Mansilla R, et al. Fungal keratitis in Northwestern Spain: epidemiology, risk factors and outcomes. J Fungi (Basel). 2024;10(10):689.
Lamas-Francis D, Treviño M, Pérez-Freixo H, et al. Corneal ulcer due to monkeypox infection. Ocul Immunol Inflamm. 2024;32(3):259-261.
Lamas-Francis D, Rodríguez-Fernández CA, de Esteban-Maciñeira E, et al. Impact of driver mutations on metastasis-free survival in uveal melanoma: a meta-analysis. Cancers (Basel). 2024;16(14):2510.
Lamas-Francis D, Navarro D, Moreno C, et al. Amniotic membrane transplantation in corneal ulceration following infectious keratitis. Ocul Immunol Inflamm. 2024;32(7):1261-1267.
Lamas-Francis D, Rodríguez-Fernández CA, Bande M, Blanco-Teijeiro MJ. Foveal microvascular features after inverted flap technique for large macular holes. Eur J Ophthalmol. 2024;34(1):260-266.
Tourino-Peralba R, Lamas-Francis D, Freijeiro-Gonzalez L, et al. Can the location of the iris claw lens influence pseudophakic macular edema? Clin Ophthalmol. 2024;18:2637-2644.
Lamas-Francis D, Bande-Rodríguez M, Blanco-Teijeiro MJ. Primary ILM peeling during retinal detachment repair: a systematic review and meta-analysis. Sci Rep. 2023;13(1):3586.
Lamas-Francis D, Llovo-Taboada J, Navarro D, et al. Necrotizing scleritis due to Hormographiella aspergillata. Eur J Ophthalmol. 2023;33(5):NP71-NP74.
Rodríguez-Ares T, Lamas-Francis D, Treviño M, et al. SARS-CoV-2 in conjunctiva and tears an ocular symptoms in COVID-19. Vision (Basel). 2021;5(4):51.
Rodríguez-Ares MT, Touriño R, Lamas-Francis D, et al. Hand sanitiser-associated ocular chemical injury in children. J Paediatr Child Health. 2021;57(12):2008-2009.
Touriño Peralba R, Lamas-Francis D, Sarandeses-Diez T, et al. Iris-claw intraocular lens for aphakia: can location influence final outcomes? J Cataract Refract Surg. 2018;44(7):818-826